FAVALLI, ENNIO GIULIO
FAVALLI, ENNIO GIULIO
Dipartimento di Scienze Cliniche e di Comunità
Early recognition of peripheral spondyloarthritis in inflammatory bowel disease: A prospective observational study integrating detail questionnaire screening, ultrasound-based diagnosis, and gut microbiota profiling
2026 F. Santagata, M. Ferrito, E.G. Favalli, R. Caporali, O. De Lucia, I. Honcharyuk, E. Panichi, F. Conforti, N.P. O Sed, L. Spina, B. Caridi, G. Trignani, L. Ingrao, M. Vecchi, F. Caprioli
Multidisciplinary consensus on the diagnosis and management of patients with atypical Hemolytic Uremic Syndrome (complement-mediated TMA): recommendations from Italian scientific societies, patient associations and regulators
2025 E.D. Stea, M. Pugliano, R. Gualtierotti, M. Mazzucato, L. Santangelo, G. Annicchiarico, A. Berardelli, S. Bianchi, L. Bogliolo, P. Chiandotto, G. Cirino, F.D. Iaco, S.D. Rosa, F. Dentali, P. Facchin, E.G. Favalli, F. Fiorin, A. Giarratano, C. Laterza, F. Macrì, M. Mancuso, A. Padovani, A. Pasini, A.M. Scopinaro, G.D. Sebastiani, G. Sesti, B. Susi, A. Torsello, C. Vezzoni, L. Zanlari, L. Gesualdo, A.D. Luca
Expanding the expanded risk score to psoriatic arthritis: any port in a storm
2025 E.G. Favalli, L. Ingrao, G. Trignani, M. Ferrito, G. Cincinelli, R. Caporali
Whole-Blood RNA Sequencing Profiling of Patients With Rheumatoid Arthritis Treated With Tofacitinib
2025 C. Bellocchi, E.G. Favalli, G. Maioli, E. Agape, M. Rossato, M. Paini, A. Severino, B. Vigone, M. Biggioggero, E. Trombetta, R. Caporali, L. Beretta
Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry
2024 A. Manfredi, M. Fornaro, C. Bazzani, S. Perniola, A. Cauli, A. Rai, E.G. Favalli, S. Bugatti, M. Rossini, R. Foti, F. Conti, G. Lopalco, A. Scalvini, C. Garufi, M. Congia, R. Gorla, E. Gremese, F. Atzeni, R. Caporali, F. Iannone, M. Sebastiani
Difficult-to-treat psoriatic arthritis: refining the definition using a statistical model in a real-life cohort
2024 E.G. Favalli, G. Biganzoli, G. Cincinelli, M. Ferrito, E. Luconi, M. Manara, M. Biggioggero, P. Boracchi, R. Caporali
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs
2024 E.G. Favalli, G. Maioli, R. Caporali
Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients
2024 G. Cincinelli, G. Maioli, C. Posio, E.G. Favalli, F. Ingegnoli, R. Caporali
The change over time in the prescription pattern of the first targeted drug after failure of conventional therapy in patients with rheumatoid arthritis: a 20-year real-world experience
2024 G. Maioli, G. Cincinelli, M. Biggioggero, R. Caporali, E.G. Favalli
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
2023 L.M. Ornbjerg, K. Rugbjerg, S. Georgiadis, S.H. Rasmussen, U. Lindstrom, K. Pavelka, N. Yilmaz, E.G. Favalli, M.J. Nissen, B. Michelsen, E. Vieira-Sousa, G.T. Jones, R. Ionescu, H. Relas, C. Sanchez-Piedra, M. Tomsic, A.J. Geirsson, I. van der Horst-Bruinsma, J. Askling, A.G. Loft, L. Nekvindova, H. Direskeneli, F. Iannone, A. Ciurea, K.M. Fagerli, M.J. Santos, G.J. Macfarlane, C. Codreanu, K. Eklund, M. Pombo-Suarez, Z. Rotar, B. Gudbjornsson, T. Rusman, M. Ostergaard, M.L. Hetland
Rheumatoid Arthritis from Easy to Complex Disease: From the “2022 GISEA International Symposium”
2023 S. Perniola, M.S. Chimenti, F.R. Spinelli, B. Frediani, R. Foti, S. Ferrigno, C. Garufi, G. Cassone, V. Venerito, F. Atzeni, R. Caporali, F. Conti, E.G. Favalli, F. Iannone, M. Sebastiani, G.F. Ferraccioli, G. Lapadula, E. Gremese
From Bench to Bedside in Rheumatoid Arthritis from the “2022 GISEA International Symposium”
2023 A. Vitale, S. Alivernini, R. Caporali, G. Cassone, D. Bruno, L. Cantarini, G. Lopalco, M. Rossini, F. Atzeni, E.G. Favalli, F. Conti, E. Gremese, F. Iannone, G.F. Ferraccioli, G. Lapadula, M. Sebastiani
Effect of neridronate on axial involvement in patients with spondyloarthritis when biologics are not possible. Results of a monocentric study
2023 C. Crotti, R. Di Taranto, F. Orsini, M. Ferrito, M. Varenna, E.G. Favalli, R. Caporali
The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events
2023 E.G. Favalli, G. Cincinelli, S. Germinario, R. Di Taranto, F. Orsini, G. Maioli, M. Biggioggero, M. Ferrito, R. Caporali
Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission
2023 R. Giacomelli, R. Caporali, F. Ciccia, S. Colafrancesco, L. Dagna, M. Govoni, F. Iannone, P. Leccese, C. Montecucco, G. Pappagallo, G. Pistone, R. Priori, P. Ruscitti, P. Sfriso, L. Cantarini, N. Belfiore, C. Bernardi, M. Gabini, S. Bettio, A. Brucato, G. Italiano, F.P. Cantatore, D. Iacono, I. Pantano, E. Tirri, F. Ursini, A.L. Monaco, F. Caso, L. Quartuccio, M.S. Chimenti, A. Gattamelata, E. Gremese, M. Paroli, A. Picchianti-Diamanti, G.D. Sebastiani, E. Favalli, A. Sulli, M. Frassi, P. Faggioli, R. Foti, C. Campochiaro, G. Cavalli, A. Tomelleri, M. Manara, L. De Stefano, R. De Angelis, S. Parisi, G. Lopalco, M. Piga, D. Marotto, M. Colaci, A. Padula, G. Guggino, G. Emmi, C. Baldini, J. Sota, A. Vitale, A. Berti, E. Bartoloni, C. Grava, S. Bindoli, R. Vitetta
Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients
2023 M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E.G. Favalli, R. Caporali
Tight control in patients with rheumatoid arthritis treated with targeted therapies across the COVID-19 pandemic era
2023 A.F. Luppino, G. Cincinelli, A. Orenti, P. Boracchi, E.G. Favalli, R. Caporali, F. Ingegnoli
Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis
2022 S. Bugatti, L. De Stefano, B. D'Onofrio, A. Nicrosini, E. Mauric, M. Di Lernia, G. Sakellariou, E.G. Favalli, A. Manzo, R. Caporali, C. Montecucco
Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine
2022 F.R. Spinelli, E.G. Favalli, C. Garufi, M. Cornalba, S. Colafrancesco, F. Conti, R. Caporali
Immune response to SARS-COV-2 infection in patients with rheumatic musculoskeletal diseases: the mainstream study
2022 E.G. Favalli, A. Favalli, G. Andrea, G. Maioli, E. Zagato, M. Bombaci, E. Pesce, L. Donnici, P. Gruarin, M. Biggioggero, S. Curti, L. Manganaro, E. Marchisio, V. Bevilacqua, M. Martinovic, T. Fabbris, M.L. Sarnicola, M. Crosti, L. Marongiu, F. Granucci, S. Notabartolo, A. Bandera, A. Gori, R. De Francesco, S. Abrignani, R. Caporali, R. Grifantini